Study of XL999 in Adults With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors

The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.

Inclusion Criteria:

• Advanced solid tumor
• Cancer that has progressed on currently available therapies
• Life expectancy of >3 months
• Adequate bone marrow, liver, and kidney function
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

Exclusion Criteria:

• Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Radiotherapy within 4 weeks of the start of treatment
• Subjects with known brain metastasis
• Uncontrolled medical disorder such as infection or cardiovascular disease
• Subjects known to be HIV positive
• Pregnant or breastfeeding women